Clinical trials: Bronchogenic Cancer
Non Small Cell Lung Cancer
Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients
Primary: ·To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as first line treatment in patients with non-small cell bronchopulmonary cancer Secondary: ·To evaluate the toxicity of the…
- Trial name
- GON (NCT00271271)
- Testing
- oxaliplatine / gemcitabine / Vinorelbine
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Sanofi
Non Small Cell Lung Cancer
Lung Cancer Multi-omics Digital Human Avatars for Integrating Precision Medicine Into Clinical Practice
The goal of this multi-centric observational clinical trial is to to develop accurate predictive models for lung cancer patients, through the creation of Digital Human Avatars using various omics-based variables and integrating…
- Trial name
- LANTERN (NCT05802771)
- Testing
- surgical resection
- Volunteers
- 600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non Small Cell Lung Cancer
A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported.
- Trial name
- NCT04777175
- Testing
- immunity therapy
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- Yongchang Zhang
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Non-Small Cell Lung Cancer
Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)
Primary Objectives: To assess the safety of oral therapy with ZD6474 by evaluating the frequency, severity, and duration of treatment-emergent adverse events in patients with poor prognosis lung cancer.
- Trial name
- NCT00745732
- Testing
- ZD6474 (ZACTIMA), Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer (Non-Small Cell)
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Study Design: a Phase II, single-arm, multicenter, prospective, interventional study. Target Population: Subjects with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed to harbor…
- Trial name
- NCT07198841
- Testing
- IBI351 combined with cetuximab β
- Where
- 7 sites in China
- Volunteers
- 48 people
- Sponsor
- Guangdong Association of Clinical Trials
Lung Cancer
A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in…
- Trial name
- NCT03322566
- Testing
- Pembrolizumab, Epacadostat, Platinum-based chemotherapy
- Where
- 94 sites in United States, Australia and 12 more
- Volunteers
- 233 people
- Sponsor
- Incyte Corporation
Non-small Cell Lung Cancer
Study of XL999 in Patients With Non-small Cell Lung Cancer
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00277329
- Testing
- XL999
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Symphony Evolution, Inc.
Non-small Cell Lung Cancer
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who…
- Trial name
- NCT06542731
- Testing
- ONO-4578, ONO-4538, Docetaxel
- Where
- 13 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Non-Small Cell Carcinoma of Lung, Immunotherapy
Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
This study is a retrospective, multicenter, observational cohort study in patients with advanced or locally advanced non-small cell lung cancer (NSCLC).
- Conditions
- Non-Small Cell Carcinoma of Lung, Immunotherapy, Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT07668037
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer
Efficacy and Safety of Camrelizumab in Real-World Prospective Study
This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.
- Trial name
- NCT04793139
- Testing
- Camrelizumab
- Volunteers
- 1,000 people
- Sponsor
- Guangdong Association of Clinical Trials
Non Small Cell Lung Cancer, Perioperative Complication
Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment
Chemotherapy combined with immunotherapy is the current standard perioperative treatment for non-small cell lung cancer (NSCLC). However, this regimen has multiple side effects and shows variable efficacy among individuals.
- Trial name
- MSJZT-NSCLC (NCT06445881)
- Testing
- Modified Si Jun Zi Tang
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Non-Small-Cell Lung Carcinoma
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70…
- Trial name
- NCT00137800
- Testing
- OSI-774 (Tarceva)
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Non-small Cell Lung Cancer (NSCLC)
A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of first-line nivolumab plus ipilimumab treatment for locally advanced…
- Trial name
- FINN (NCT06487156)
- Testing
- Nivolumab + ipilimumab
- Where
- Italy
- Volunteers
- 404 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer
Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00103051
- Testing
- cisplatin, gefitinib, gemcitabine hydrochloride
- Where
- Netherlands
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Carcinoma, Small Cell
Temozolomide as Maintenance Therapy in Small Cell Lung Cancer
Temozolomide, a nonclassic oral alkylating agent, may delay progression in sequence with chemotherapy. This phase II trial was designed to evaluate the role of Temozolomide following 4 or 6 cycles of first-line treatment in…
- Trial name
- NCT01900951
- Testing
- Temozolomide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Carcinoma, Non-Small Cell Lung
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible.
- Trial name
- NCT04499053
- Testing
- Durvalumab, Tremelimumab
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Georgetown University
Non Small Cell Lung Cancer
Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.
- Trial name
- Cypress 2 (NCT03382912)
- Testing
- Pegilodecakin, Nivolumab
- Where
- 35 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)
This is a study from Eastern Cooperative Thoracic Oncology Project, numbered as ECTOP-1009. Systematically mediastinal lymph node dissection or not in clinical stage T1 ground-glass dominated invasive lung adenocarcinoma: a…
- Trial name
- NCT04527419
- Testing
- No mediastinal lymph node dissection
- Where
- China
- Volunteers
- 545 people
- Sponsor
- Fudan University
Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non-small cell lung cancer with and without prior treatment with immunotherapy.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT03048500
- Testing
- Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.